IPCA surges after string of broker upgrades

Tags: Ipca, Companies
Shares of IPCA Laboratories Ltd gain 4 per cent to Rs 861.30 after Morgan Stanley initiates coverage on the company with a "buy" rating and a target price of Rs 1,101, calling it its "preferred healthcare mid-cap stock."

Morgan Stanley says that IPCA's growing India business, ramp-up in anti-malaria drugs and increased capacity for the U.S. market should drive 23 percent compounded annual growth in earnings until fiscal 2016, versus an average 16.3 percent for other Indian healthcare stocks in its coverage.

IPCA has received a slew of recent upgrades from foreign banks, highlighting its improving outlook. Shares are up 18.7 percent so far this year, compared with a 3.3 percent gain in the BSE healthcare index and a 3 percent rise in the BSE Sensex.

Last month, Credit Suisse initiated coverage on IPCA with an "outperform" rating, while CLSA upgraded the stock in January to "buy" from "outperform.


  • RBI should make it must for banks to disclose loans refinanced under 5/25 scheme

    There is reasonable doubt that banks are using the 5/25 scheme to postpone dealing with bad loans.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


BK Chaturvedi

Bihar, development and governance

Chief minister Nitish Kumar won the recent Bihar election with ...

Kuruvilla Pandikattu

The miracle of miracles

In 1966 Time magazine ran a cover story asking: Is ...

Dharmendra Khandal

Mosquitoes are a menace, but part of eco system too

Who can deny that mosquitoes are a menace? The buzz ...


William D. Green

Chairman & CEO, Accenture